2M.D. Asistant, Mustafa Kemal University Faculty of Medicine, Department of Ophthalmology, Hatay/TURKEY
3M.D. Asistant Professor, Bezmialem Vakif University Faculty of Medicine, Department of Ophthalmology, İstanbul/TURKEY Purpose: To investigate the effect of ranibizumab a vascular endothelial growth factor inhibitor - on intraocular pressure.
Material and Methods: Records of sixty-one eyes of 56 patients received intravitreal ranibizumab injection due to exudative age-related macular degeneration were investigated, retrospectively. Intraocular pressures measured 1 day, 1, 3 and 6 months after the injection were evaluated. There was no significant difference among intraocular pressure values measured before and after the injections.
Results: The mean age of the patients was 72.6±7.5. Sixty one eye received intravitreal ranibizumab injection. The follow-up duration was 6 months. all the patients had intraocular pressure lower than 21 mmHg at first dat after the injection. At first month and third month, there was only one patient having intraocular pressure higher than 21 mmHg. . There was no significant difference among intraocular pressure values measured before and after the injections.
Conclusion: Although intravitreal ranibizumab injection has no effect on intraocular pressure, few cases may have increased intraocular pressure.
Keywords : Ranibizumab, intravitreal enjection, age-related macular degeneration, intraocular pressure